Equities

Medicamen Biotech Ltd

MEDICAMEQ:NSI

Medicamen Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)462.95
  • Today's Change11.95 / 2.65%
  • Shares traded51.91k
  • 1 Year change-30.90%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 11:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments14820838
Total Receivables, Net787887848
Total Inventory598476270
Prepaid expenses323239
Other current assets, total303135
Total current assets1,5961,6341,230
Property, plant & equipment, net910918921
Goodwill, net------
Intangibles, net8.988.983.60
Long term investments------
Note receivable - long term--118.65
Other long term assets33912511
Total assets2,9462,7852,257
LIABILITIES
Accounts payable389476433
Accrued expenses------
Notes payable/short-term debt296233193
Current portion long-term debt/capital leases2.941514
Other current liabilities, total15810187
Total current liabilities846826727
Total long term debt138.7051
Total debt311257258
Deferred income tax------
Minority interest------
Other liabilities, total181715
Total liabilities876851792
SHAREHOLDERS EQUITY
Common stock127127122
Additional paid-in capital1,023981677
Retained earnings (accumulated deficit)920827665
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity2,0701,9341,465
Total liabilities & shareholders' equity2,9462,7852,257
Total common shares outstanding131312
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.